Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 76

Results For "SPI"

2735 News Found

QMS Medical Allied Services reports 31.65% rise in Q1 FY26 PAT to Rs. 3.15 Cr
News | August 17, 2025

QMS Medical Allied Services reports 31.65% rise in Q1 FY26 PAT to Rs. 3.15 Cr

The company’s acquisition of a 51 per cent stake in Saarathi Healthcare earlier this financial year boosted growth


UFlex posts Q1 FY26 PAT at Rs. 58 Cr
News | August 17, 2025

UFlex posts Q1 FY26 PAT at Rs. 58 Cr

The company’s virgin PET chips plant in Egypt, commissioned in Q4 FY25, achieved 74.8 per cent capacity utilization in its first full quarter. In India, the Panipat facility operated at 96.6 per cent utilization


Indoco Remedies receives final USFDA approval for rivaroxaban tablets
Drug Approval | August 13, 2025

Indoco Remedies receives final USFDA approval for rivaroxaban tablets

Rivaroxaban is used to treat venous thromboembolism


Senores Pharmaceuticals acquires ANDAs from Teva Pharmaceuticals USA
News | August 13, 2025

Senores Pharmaceuticals acquires ANDAs from Teva Pharmaceuticals USA

The acquired ANDAs represent a market opportunity of about US$ 38 million in the USA


Zydus Lifesciences reports Q1 FY26 net profit at Rs. 1,466.8 Cr
News | August 13, 2025

Zydus Lifesciences reports Q1 FY26 net profit at Rs. 1,466.8 Cr

The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY


Pfizer launches 20-valent Pneumococcal Conjugate Vaccine for adults in India
News | August 12, 2025

Pfizer launches 20-valent Pneumococcal Conjugate Vaccine for adults in India

Pfizer's vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease


Glenmark Pharmaceuticals reached $37.75 million settlement in antitrust litigation in US
News | August 12, 2025

Glenmark Pharmaceuticals reached $37.75 million settlement in antitrust litigation in US

Glenmark USA is named in multiple antitrust and consumer protection lawsuits, including class actions, consolidated in the Eastern District of Pennsylvania, U.S


Aurobindo Pharma Q1 FY26 PAT slips 10% YoY to Rs. 824 Cr
News | August 10, 2025

Aurobindo Pharma Q1 FY26 PAT slips 10% YoY to Rs. 824 Cr

Aurobindo Pharma’s US formulations revenue slipped 1.9% on a year-on-year basis to Rs. 3,488 crore


Akums reports Q1 FY26 PAT at Rs. 65 Cr
News | August 09, 2025

Akums reports Q1 FY26 PAT at Rs. 65 Cr

During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals